APRINOIA Therapeutics Inc. (APRI)
APRINOIA Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$10.00 - $14.00
Shares Offered
2,000,000
Deal Size
$24.00M
Company Description
APRINOIA Therapeutics is a clinical-stage biotechnology company committed to protecting patients’ brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics.
In harnessing the power of precision neuroscience, we are developing several different diagnostic and therapeutic platforms to detect and target both common and neurodegenerative disorders marked by abnormal protein aggregates of tau and alpha-synuclein (“α-Syn”) that are toxic to brain cells.
APRINOIA Therapeutics Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Mark S. Shearman, Ph.D. |
Contact Details
Address: 245 Main Street, 2nd Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617-225-4415 |
| Website | aprinoia.com |
Stock Details
| Ticker Symbol | APRI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001998311 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ming-Kuei Jang, Ph.D. | Chairman of the Board of Directors |
| Mark S. Shearman, Ph.D. | Director and Chief Executive Officer |
| Kuk-Hyun Kyung, B.S. | Director |
| Michael Xin Hui, M.B.A. | Director |
| Zhigang Luo, M.B.A. | Director |
| Roger James Pomerantz, M.D., F.A.C.P. | Director |
| Bradford A. Navia, M.D., Ph.D. | Chief Medical Officer |
| Brian Achenbach, M.B.A. | Chief Financial Officer |
| Lana Gladstein, J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Mar 1, 2024 | FWP | Free Writing Prospectus |
| Feb 26, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 26, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Dec 29, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 13, 2023 | DRS | [Cover] Draft Registration Statement |